Home / About / Join Our Team / Contact / 610-431-5000

Medical Services Locations Patient/Visitor Info Programs & Support Points of Pride
Renal (Kidney) Cancer

Home > Medical Services > Cancer Program > Clinical Trials

SWOG S0931

Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery

Last Modified: 6/5/2012 First Published: 5/6/2010

Trial Description


Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor.

This phase III trial is studying everolimus to see how well it works in treating patients with kidney cancer who have undergone surgery.

Eligibility criteriainclude the following:

Final eligibility for a clinical trial is determined by the health professionals conducting the trial.


Patients will be randomly assigned (have an equal chance of being placed to) one of two treatment groups.

Patients in group one will receive everolimus by mouth once daily. Treatment may continue for 54 weeks.

Patients in group two will receive placebo by mouth once daily. Treatment may continue for 54 weeks.

Tumor tissue, plasma, and blood samples may be collected periodically for laboratory studies.

After finishing treatment, patients will be evaluated every 6 months for 2 years and then once a year for 8 years.

Trial Contact Information

Blanche Reiner RN OCN 610-738-2515
Nona Blauvelt MSN AOCN 610-738-2522

Last Updated: 7/16/2012